NVNO earnings analysis
What we found in NVNO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
enVVeno Medical Corporation reported a significant net loss of $3.85 million for Q1 2026, showing a 15% improvement compared to $4.50 million in Q1 2025. Operating expenses decreased as the company shifts focus towards its enVVe system after FDA IDE approval, but it continues to struggle with no revenue generation, consistent with its developmental stage. Cash and investments decreased to approximately $24.9 million, along with a cash burn rate projected to rise between $4 million and $5 million per quarter in 2026.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Net Loss Improvement
- Net loss reduced to $3.85 million in Q1 2026 from $4.50 million in Q1 2025.
- Cash Reserves Status
- Total cash and investments decreased to $24.9 million from $28.2 million at year-end 2025.
- Decreased Operating Expenses
- Operating expenses decreased by 22% year-over-year, totaling approximately $4.1 million.
- FDA IDE Approval Milestone
- The FDA approved the enVVe system's IDE application, allowing pivotal study commencement.
- Continued Zero Revenue
- As a developmental company, enVVeno continues to report zero revenue.
- Operating Cash Flow Reduction
- Cash used in operating activities decreased to $3.2 million from $4.0 million year-over-year.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ongoing Cash Burn Concerns
- Projected cash burn of $4-$5 million per quarter could strain liquidity beyond 2027.
- No Revenue Generation
- Continues to operate without revenue, which poses risks to sustaining operations long-term.
- Regulatory Approval Dependency
- Future revenue relies on potential FDA approval for the enVVe system; current revenues are $0.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-5.89
- Segment
- Medical Device Development
What they said about what is next.
Management anticipates operating losses will continue; cash burn projected at $4-$5 million per quarter in 2026.
The filing reads worse than the one before it.
What came before.
- 10-K · March 26, 2026
- enVVeno is a pre-revenue medical device company that pivoted after an August 19, 2025 FDA not-approvable letter for VenoValve to a next‑generation transcatheter enVVe System (pre-clinical testing complete; pivotal trial…
- 10-K · February 29, 2024
- enVVeno (NVNO) is a late-clinical stage medical device company focused on first-in-class surgical (VenoValve) and transcatheter (enVVe) replacement venous valves for severe deep venous chronic venous insufficiency. The…
- 10-Q · July 31, 2023
- enVVeno (NVNO) reported no revenue and a quarterly net loss of $(6,474) (Q2 2023), an improvement versus $(7,062) in Q2 2022; GAAP loss per share improved to $(0.58) from $(0.63). Management reduced SG&A to $2,600 (Q2…
- 10-Q · October 27, 2022
- EnVVeno (NVNO) reported no product revenue and a wider quarterly loss: net loss was $6,097,000 ( $(0.54) per share) in Q3 2022 versus $2,389,000 ( $(0.26) ) in Q3 2021. Operating losses rose as SG&A increased to…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NVNO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever